Menu Menu

Caring for people with Monkeypox (MPX)

Supporting Australia’s healthcare professionals with evidence-based clinical guidelines

On 18 May 2023, NCET took the decision to retire the MPX Living Guidelines for the foreseeable future, given the national and international health and research landscapes. A few weeks earlier, WHO director-general Tedros Adhanom Ghebreyesus announced that MPX was no longer a public health emergency of international concern and pointed to global progress in controlling the outbreaks in recent months. There are currently very few cases of MPX in Australia, there is scant evidence on MPX being published globally, and the major trials we do know of will not be reporting until much later in 2023. We look forward to exploring the findings from more significant studies when they are published in late 2023.

In the meantime, the MPX Guidelines remain freely accessible but as at May 2023, are not being regularly updated. You can find out more about our MPX work and decision to retire them in our news section.

22/05/23: Communique from the National Steering Committee

Please note:

As of 31 July 2023, the National Clinical Evidence Taskforce is no longer funded. The COVID-19 and MPX guidelines are still accessible online, but are not currently being updated.

For more information and the latest developments in Australian living evidence visit livingevidence.org.au

MPX
guidelines

Evidence-based clinical Monkeypox (MPX) guidelines updated with the latest research

Expert Panels

Do you have a clinical question?

Your views help us to identify and prioritise questions to include in the living guideline.

envelope iconSubscribe here to receive regular updates from the Taskforce

PERSONAL DETAILS

Please enter your email, so we can follow up with you.

SUGGESTIONS

Suggest a new topic or clinical question. Please note that our living guideline aims to

“Provide specific, patient-focused recommendations for the clinical care of people with suspected or confirmed COVID-19, where care for this patient group differs from usual care provided to patients with similar clinical conditions (pneumonia, severe acute respiratory distress, etc.)”.


*The following topics for COVID-19 are currently included:

• Definition of disease severity
• Monitoring and markers of clinical deterioration
• Drug treatments (e.g. antimalarials)
• Chemoprophylaxis
• Respiratory support in adults
• Respiratory support in neonates, children and adolescents
• Venous thromboembolism (VTE) prophylaxis
• Therapies for existing indications in patients with COVID-19
• Care of people after COVID-19
• Timing of surgery following COVID-19 infection
• Pregnancy and perinatal care
• Child and adolescent care

*The following topics for MPX are currently included:

• Disease severity and risk of severe disease
• Drug treatments
• Supportive care
• Pregnancy and perinatal care
• Paediatric and adolescent care

AGREEMENTS

Please enter your email to receive our regular updates.

Partners
and funders